I-Mab (IMAB)
NASDAQ: IMAB
· Real-Time Price · USD
3.48
-0.04 (-1.14%)
At close: Sep 26, 2025, 10:58 AM
-1.14% (1D)
| Bid | 3.46 |
| Market Cap | 283.77M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -38.21M |
| EPS (ttm) | -0.51 |
| PE Ratio (ttm) | -6.81 |
| Forward PE | -1.78 |
| Analyst | Buy |
| Dividends | n/a |
| Ask | 3.49 |
| Volume | 128,423 |
| Avg. Volume (20D) | 2,155,998 |
| Open | 3.55 |
| Previous Close | 3.52 |
| Day's Range | 3.46 - 3.60 |
| 52-Week Range | 0.59 - 5.90 |
| Beta | 1.37 |
| Ex-Dividend Date | n/a |
About IMAB
undefined
Industry n/a
Sector n/a
IPO Date n/a
Employees NaN
Stock Exchange n/a
Ticker Symbol IMAB
Website n/a
Analyst Forecast
According to 0 analyst ratings, the average rating for IMAB stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.
Stock Forecasts1 month ago
+8.07%
I-MAB shares are trading higher on possible contin...
Unlock content with
Pro Subscription
1 month ago
+30.35%
I-MAB shares are trading higher after the company announced that Everest will invest $30.9 million in the company. Additionally, the company announced a $65 million ADS offering.
2 weeks ago · seekingalpha.com
I-Mab: Sudden Pivot To Gastric Cancer Med Still Underappreciated By MarketI-Mab has pivoted to focus on givastomig for gastric cancer, after divesting its original China portfolio and revamping leadership. Givastomig shows superior early efficacy versus rivals, with promisi...
